PHARMANUTRA SPA (PHN.MI) Stock Fundamental Analysis
Europe - Euronext Milan - BIT:PHN - IT0005274094 - Common Stock
64.3 EUR
-0.6 (-0.92%)
Taking everything into account, PHN scores 7 out of 10 in our fundamental rating. PHN was compared to 13 industry peers in the Personal Care Products industry. PHN has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. PHN is quite expensive at the moment. It does show a decent growth rate. With these ratings, PHN could be worth investigating further for quality investing!.
1. Profitability
1.1 Basic Checks
- PHN had positive earnings in the past year.
- In the past year PHN had a positive cash flow from operations.
- In the past 5 years PHN has always been profitable.
- In the past 5 years PHN always reported a positive cash flow from operatings.
1.2 Ratios
- PHN has a better Return On Assets (20.17%) than 100.00% of its industry peers.
- PHN has a better Return On Equity (36.55%) than 100.00% of its industry peers.
- PHN has a Return On Invested Capital of 25.72%. This is amongst the best in the industry. PHN outperforms 100.00% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for PHN is significantly above the industry average of 11.91%.
- The last Return On Invested Capital (25.72%) for PHN is above the 3 year average (17.21%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.17% | ||
| ROE | 36.55% | ||
| ROIC | 25.72% |
ROA(3y)13.53%
ROA(5y)17.42%
ROE(3y)26.61%
ROE(5y)29.54%
ROIC(3y)17.21%
ROIC(5y)18.21%
1.3 Margins
- PHN has a Profit Margin of 13.39%. This is in the better half of the industry: PHN outperforms 76.92% of its industry peers.
- In the last couple of years the Profit Margin of PHN has declined.
- The Operating Margin of PHN (21.79%) is better than 100.00% of its industry peers.
- In the last couple of years the Operating Margin of PHN has remained more or less at the same level.
- With an excellent Gross Margin value of 97.13%, PHN belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
- PHN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.79% | ||
| PM (TTM) | 13.39% | ||
| GM | 97.13% |
OM growth 3Y-4.84%
OM growth 5Y1.01%
PM growth 3Y-10.74%
PM growth 5Y-1.82%
GM growth 3Y-0.75%
GM growth 5Y-0.04%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so PHN is creating value.
- PHN has about the same amout of shares outstanding than it did 1 year ago.
- PHN has less shares outstanding than it did 5 years ago.
- PHN has a better debt/assets ratio than last year.
2.2 Solvency
- An Altman-Z score of 10.80 indicates that PHN is not in any danger for bankruptcy at the moment.
- PHN has a better Altman-Z score (10.80) than 100.00% of its industry peers.
- PHN has a debt to FCF ratio of 2.01. This is a good value and a sign of high solvency as PHN would need 2.01 years to pay back of all of its debts.
- With a decent Debt to FCF ratio value of 2.01, PHN is doing good in the industry, outperforming 69.23% of the companies in the same industry.
- A Debt/Equity ratio of 0.24 indicates that PHN is not too dependend on debt financing.
- PHN has a Debt to Equity ratio of 0.24. This is in the better half of the industry: PHN outperforms 69.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.24 | ||
| Debt/FCF | 2.01 | ||
| Altman-Z | 10.8 |
ROIC/WACC3.22
WACC7.98%
2.3 Liquidity
- A Current Ratio of 2.19 indicates that PHN has no problem at all paying its short term obligations.
- Looking at the Current ratio, with a value of 2.19, PHN belongs to the top of the industry, outperforming 92.31% of the companies in the same industry.
- A Quick Ratio of 1.86 indicates that PHN should not have too much problems paying its short term obligations.
- PHN's Quick ratio of 1.86 is amongst the best of the industry. PHN outperforms 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.19 | ||
| Quick Ratio | 1.86 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an nice 12.84% over the past year.
- The Earnings Per Share has been growing by 14.63% on average over the past years. This is quite good.
- Looking at the last year, PHN shows a quite strong growth in Revenue. The Revenue has grown by 14.35% in the last year.
- Measured over the past years, PHN shows a quite strong growth in Revenue. The Revenue has been growing by 16.59% on average per year.
EPS 1Y (TTM)12.84%
EPS 3Y6.71%
EPS 5Y14.63%
EPS Q2Q%13.11%
Revenue 1Y (TTM)14.35%
Revenue growth 3Y19.25%
Revenue growth 5Y16.59%
Sales Q2Q%19.45%
3.2 Future
- The Earnings Per Share is expected to grow by 15.13% on average over the next years. This is quite good.
- Based on estimates for the next years, PHN will show a quite strong growth in Revenue. The Revenue will grow by 13.74% on average per year.
EPS Next Y6.25%
EPS Next 2Y13.31%
EPS Next 3Y15.13%
EPS Next 5YN/A
Revenue Next Year14.8%
Revenue Next 2Y14.39%
Revenue Next 3Y14.28%
Revenue Next 5Y13.74%
3.3 Evolution
- The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
- The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 25.62, PHN can be considered very expensive at the moment.
- PHN's Price/Earnings ratio is in line with the industry average.
- PHN is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.25, which is the current average of the S&P500 Index.
- Based on the Price/Forward Earnings ratio of 26.33, the valuation of PHN can be described as expensive.
- Based on the Price/Forward Earnings ratio, PHN is valued a bit more expensive than 61.54% of the companies in the same industry.
- PHN is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 25.98, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.62 | ||
| Fwd PE | 26.33 |
4.2 Price Multiples
- PHN's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. PHN is more expensive than 69.23% of the companies in the same industry.
- PHN's Price/Free Cash Flow ratio is a bit more expensive when compared to the industry. PHN is more expensive than 76.92% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 59.71 | ||
| EV/EBITDA | 14.45 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- The excellent profitability rating of PHN may justify a higher PE ratio.
- A more expensive valuation may be justified as PHN's earnings are expected to grow with 15.13% in the coming years.
PEG (NY)4.1
PEG (5Y)1.75
EPS Next 2Y13.31%
EPS Next 3Y15.13%
5. Dividend
5.1 Amount
- With a Yearly Dividend Yield of 1.52%, PHN has a reasonable but not impressive dividend return.
- PHN's Dividend Yield is slightly below the industry average, which is at 2.23.
- PHN's Dividend Yield is comparable with the S&P500 average which is at 1.82.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.52% |
5.2 History
- On average, the dividend of PHN grows each year by 11.21%, which is quite nice.
Dividend Growth(5Y)11.21%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
- PHN pays out 39.70% of its income as dividend. This is a sustainable payout ratio.
- PHN's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP39.7%
EPS Next 2Y13.31%
EPS Next 3Y15.13%
PHARMANUTRA SPA / PHN.MI FAQ
What is the fundamental rating for PHN stock?
ChartMill assigns a fundamental rating of 7 / 10 to PHN.MI.
Can you provide the valuation status for PHARMANUTRA SPA?
ChartMill assigns a valuation rating of 2 / 10 to PHARMANUTRA SPA (PHN.MI). This can be considered as Overvalued.
What is the profitability of PHN stock?
PHARMANUTRA SPA (PHN.MI) has a profitability rating of 8 / 10.
How financially healthy is PHARMANUTRA SPA?
The financial health rating of PHARMANUTRA SPA (PHN.MI) is 8 / 10.
Is the dividend of PHARMANUTRA SPA sustainable?
The dividend rating of PHARMANUTRA SPA (PHN.MI) is 5 / 10 and the dividend payout ratio is 39.7%.